Werfen receives CE mark for Aptiva Antiphospholipid Syndrome reagents
New Aptiva® APS IgG and APS IgM reagents enable early diagnosis of Antiphospholipid Syndrome in hard-to-diagnose autoimmune disease
12 Mar 2024
Product news
Werfen has received a CE mark for its Aptiva® Antiphospholipid Syndrome (APS) Immunoglobulin G (IgG) and Immunoglobulin M (IgM) reagents under the European Union's (EU) In Vitro Diagnostic Medical Devices Regulation (IVDR).
The Aptiva APS IgG and APS IgM reagents are immunoassays that utilize Aptiva particle-based multi-analyte technology (PMAT) for the semi-quantitative determination of anti-cardiolipin (aCL) and anti-beta 2 glycoprotein 1 (aβ2GP1) IgG and IgM autoantibodies in human serum and citrated plasma. They are used as an aid in the diagnosis of primary and secondary APS, when used in conjunction with other laboratory findings.
The new Aptiva APS reagents complement Werfen's previously registered Aptiva Celiac Disease and Connective Tissue Diseases (CTD) Essential reagents and expand the number of CE Marked analytes detected by Aptiva to 19.
In addition to the APS, CTD and Celiac Disease assays, Aptiva will target additional autoimmune disease states, and has over 60 analytes in various stages of advanced development. These analytes have the potential to improve the accuracy of autoimmune disease diagnosis and support better patient management.
The Aptiva system is a fully automated multi-analyte system that represents the next generation of high-throughput analyzers for the autoimmunity and immunology laboratory.
Aptiva uses particle-based multi-analyte technology to deliver up to 120 APS results per hour. With PMAT, Aptiva enables the laboratory to complete its workload faster and with minimal hands-on time.